SARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Epsilon Variant

Reference:
Size

10ug, 100ug

Brand

Product type

Host Species

Description of SARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Variant

Description of SARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Variant

General information on SARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Variant

A new emerging variant of SARS-CoV-2, named CAL.20C or lineage B.1.429, was recently reported in California (US). Identified by researchers at Cedars-Sinai Medical Center in July 2020, the variant was initially reported as rare only to resurface later that year (October). The most recent reports indicate CAL.20C is swiftly replacing the former lineage 20G – the dominant variant of the region until then.
Unpublished data suggest this variant may account for almost half of the virus genome samples collected in the Los Angeles region alone throughout January 2021. Moreover, scientists suspect this lineage to be responsible for a resurgence of cases. The new strain is characterized by multiple mutations on the spike protein. Although the impact of these mutations on human-to-human transmissibility and disease severity is yet unknown, experts have urged international authorities to keep a close track of its spread.
CAL.20C is characterized by the presence of five non-synonymous amino acid changes: one observed within the receptor-binding domain (RBD) – L452R; two other mutations detected outside the RBD – S13I and W152; and the remaining mutations in ORF1ab (I4205V and B1183Y). So far, the strain has only shown a sustained spread in California (primarily in Southern California), with only a few genomes reported in Australia, New Zealand, and the UK.
Mutation L452R in the RBD is particularly worrisome due to being located in a key amino acid residue. Although it was still not proved this mutation has an impact in affinity to the human ACE2, it has already been shown that it makes the virus more resistant to some neutralizing monoclonal antibodies. Thus, it is highly likely that the L452R amino acid change enhances SARS-CoV-2’s ability to evade the human immune response. At the moment, the impact of this mutation on vaccine efficacy is currently being investigated.

Product nameSARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Epsilon Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage B.1.429,GH452R.V1, CAL.20C, Californian variant, CAL variant, Epsilon variant
ReferencePX-COV-P055
NoteFor research use only. Not suitable for in vitro diagnostic and human use.
Product nameSARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Epsilon Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage B.1.429,GH452R.V1, CAL.20C, Californian variant, CAL variant, Epsilon variant
ReferencePX-COV-P055
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

Reviews

There are no reviews yet.

Be the first to review “SARS-CoV-2 RBD of Spike protein, CAL.20C, L452R – lineage B.1.429 – CAL Epsilon Variant”

Your email address will not be published.

Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: